Compounds > 16-fluoroestradiol
Page last updated: 2024-12-06

16-fluoroestradiol

Description

16-fluoroestradiol is a synthetic analog of estradiol, the most potent natural estrogen. It has been studied for its potential use in treating breast cancer, as it exhibits antiproliferative activity against estrogen-dependent breast cancer cells. Its synthesis involves fluorination of the estradiol molecule at the 16-position, modifying its binding affinity to estrogen receptors. This modification alters its activity and pharmacodynamic properties, impacting its interaction with estrogen receptors. The compound is studied for its potential therapeutic applications in breast cancer treatment, as well as for understanding the role of estrogen signaling in various biological processes.'

16-fluoroestradiol: RN refers to (16beta,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67101
CHEMBL ID1627847
SCHEMBL ID6543617
MeSH IDM0127837

Synonyms (10)

Synonym
16-fluoroestradiol
84693-92-5
CHEMBL1627847
estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-, (16beta,17beta)-
16beta-fluoroestradiol
16alpha-(18)-fluoro-17beta-estradiol
f-18 16alpha-fluoroestradiol
SCHEMBL6543617
DTXSID101004983
16-fluoroestra-1(10),2,4-triene-3,17-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID19785Tested in vivo for the biodistribution in rat muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 ug of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24388Tested in vivo for the biodistribution in rat bone after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19395Tested in vivo for the biodistribution in blood of female rat at 1 hour after intravenous dose of 120 microCi of the drug and 15 u g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19602Tested in vivo for the biodistribution in rat kidney at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24236Partition coefficient (logP)1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID35537Relative binding affinity for Alphafetoprotein1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19791Tested in vivo for the biodistribution in rat ovaries after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID69676Relative binding affinity for estrogen receptor at 0C1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID16668Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19612Tested in vivo for the biodistribution in rat liver at 1 hour after intravenous dose of 120 microCi of the drug and 15 u g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24579Tested in vivo for the biodistribution in rat muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24574Tested in vivo for the biodistribution in rat liver after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24581Tested in vivo for the biodistribution in rat ovaries at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19816Tested in vivo for the biodistribution in rat uterus/blood after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID16657Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24582Tested in vivo for the biodistribution in rat ovaries at 1 hour after intravenous dose of 120 microCi of the drug and 15 ug of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID39321Relative binding affinity (RBA) against androgen receptor (AR) using [3H]R-1881 as competitive radioligand.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.
AID227715Binding selectivity index (BSI) as the relative affinity for estrogen receptor at 25 degree C and no-specific binding1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24389Tested in vivo for the biodistribution in rat bone at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID69389Nonspecific binding affinity (NSB) for estrogen receptor1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19597Tested in vivo for the biodistribution in rat kidney after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID16663Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24576Tested in vivo for the biodistribution in rat liver at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19394Tested in vivo for the biodistribution in blood of female rat at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24577Tested in vivo for the biodistribution in rat muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24393Tested in vivo for the biodistribution in rat kidney at 1 hour after intravenous dose of 120 microCi of the drug and 15 u g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19805Tested in vivo for the biodistribution in rat uterus after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19821Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 120 microCi of the drug and 15 ug of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19586Tested in vivo for the biodistribution in rat fat after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19580Tested in vivo for the biodistribution in rat bone at 1 hour after intravenous dose of 120 microCi of the drug and 15 ug of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID16662Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24587Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID24392Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID69677Relative binding affinity for estrogen receptor at 25 degree C1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID200434Relative binding affinity against sex steroid binding protein (SBP)1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19810Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19591Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID19389Tested in vivo for the biodistribution in blood of female rat after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (81)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (6.17)18.7374
1990's17 (20.99)18.2507
2000's17 (20.99)29.6817
2010's40 (49.38)24.3611
2020's2 (2.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.59 (24.57)
Research Supply Index4.52 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (10.98%)5.53%
Reviews11 (13.41%)6.00%
Case Studies7 (8.54%)4.05%
Observational0 (0.00%)0.25%
Other55 (67.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
choline
[no description available]		3.1310cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		1.9910elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
dihydroxyphenylalanine
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.		3.1310hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative		human metabolite
hexestrol
[no description available]		1.9610stilbenoid
fluoroacetic acid
fluoroacetic acid: N1 same as NM; RN given refers to parent cpd. fluoroacetic acid : A haloacetic acid that is acetic acid in which one of the methyl hydrogens is substituted by fluorine.		3.1310haloacetic acid;
organofluorine compound		EC 4.2.1.3 (aconitate hydratase) inhibitor
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		1.991016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		1.981017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
9,10-dimethyl-1,2-benzanthracene
9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.		2.3920ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		3.2510ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		2.0610aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		1.981017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		1.981017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9910dihydrogen
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.6630diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
alovudine
[no description available]		4.3630pyrimidine 2',3'-dideoxyribonucleoside
fluorodopa f 18
fluorodopa F 18: RN given refers to (L)-isomer		3.1310(18)F radiopharmaceutical;
6-fluoro-L-dopa
methionine methyl ester
[no description available]		2.0610
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		11.562442-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		3.683017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		1.9810
21-fluoro-16-ethyl-19-norprogesterone
21-fluoro-16-ethyl-19-norprogesterone: RN given refers to 16alpha-isomer; RN for cpd without isomeric designation not available 8/88		3.0910
1-fluorohexestrol
1-fluorohexestrol: estrogen-receptor-based agent for imaging of human breast tumors; RN given refers to (R*,S*)-isomer		1.9610
metribolone
Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.		1.981017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
fluorocholine
fluorocholine: a radiopharmaceutical agent		3.1310
n-succinimidyl-4-fluorobenzoate
N-succinimidyl-4-fluorobenzoate: used to label proteins with F(18); structure in first source; RN refers to 18F-labeled isomer		2.110
tamoxifen
[no description available]		8.0691stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
4-hydroxy-n-desmethyltamoxifen
4-hydroxy-N-desmethyltamoxifen: metabolite of tamoxifen in human bile		3.5311stilbenoid
16-fluoroestradiol, (16alpha,17beta)-isomer
[no description available]		1.9810
moxestrol
moxestrol: RN given refers to (11beta,17alpha)-isomer; structure		1.98103-hydroxy steroid
vasoactive intestinal peptide
Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		01.9810
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9810
Breast Cancer
[description not available]		013.33454
Breast Neoplasms
Tumors or cancer of the human BREAST.		013.33454
Benign Neoplasms, Brain
[description not available]		02.3110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.3110
Leiomyomatosis
The state of having multiple leiomyomas throughout the body. (Stedman, 25th ed)		02.1510
Carcinoma, Lobular
A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.		03.730
Benign Neoplasms
[description not available]		03.8620
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.8620
Idiopathic Parkinson Disease
[description not available]		03.5611
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		03.5611
Diffuse Large B-Cell Lymphoma
[description not available]		02.1710
Multiple Primary Neoplasms
[description not available]		02.1710
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		02.1710
Recrudescence
[description not available]		03.1210
Metastase
[description not available]		06.9761
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		06.9761
Atypical Endometrial Hyperplasia
A benign form of endometrial hyperplasia with increased number of cells with atypia. The atypical cells are large and irregular and have an increased nuclear/cytoplasmic ratio. The risk of progression to endometrial carcinoma rises with the increasing degree of cell atypia.		02.4920
Cancer of Endometrium
[description not available]		06.6342
Endometrial Hyperplasia
Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.		02.4920
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		06.6342
Fibroid
[description not available]		04.4222
Sarcoma, Epithelioid
[description not available]		04.7332
Cancer of the Uterus
[description not available]		05.8742
Leiomyoma
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.		04.4222
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		04.7332
Uterine Neoplasms
Tumors or cancer of the UTERUS.		05.8742
Lymph Node Metastasis
[description not available]		04.2420
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0810
Animal Mammary Carcinoma
[description not available]		02.0810
Invasiveness, Neoplasm
[description not available]		03.4711
Carcinoma, Anaplastic
[description not available]		02.0810
Cancer of Colon
[description not available]		02.0810
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.0810
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0810
Epithelial Ovarian Cancer
[description not available]		02.1110
Epithelial Neoplasms
[description not available]		02.1110
Cancer of Ovary
[description not available]		03.4320
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.1110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		03.4320
Cancer of Cervix
[description not available]		03.0310
Local Neoplasm Recurrence
[description not available]		04.3640
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		03.0310
Carcinoma, Ductal, Breast
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.		03.9120
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		06.5261
Endometrioma
An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.		02.1310
Endometriosis
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.		02.1310
Breast Cancer, Male
[description not available]		03.5311
Female Genital Neoplasms
[description not available]		03.5311
Genital Neoplasms, Female
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).		03.5311
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.		03.5311
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		02.0610
Adenocarcinoma, Basal Cell
[description not available]		04.0930
Experimental Mammary Neoplasms
[description not available]		02.9240
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		04.0930
Bone Cancer
[description not available]		06.3190
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		06.3190
Cancer of Stomach
[description not available]		02.0310
Linitis Plastica
A condition where the stomach wall becomes thickened, rubbery and loses its ability to distend. The stomach assumes a leather bottle shape. It is most often seen in adenocarcinoma of the stomach. The term is often used synonymously with diffuse adenocarcinoma of the stomach.		02.0310
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.0310
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.3920
Benign Meningeal Neoplasms
[description not available]		01.9910
Angioblastic Meningioma
[description not available]		01.9910
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		01.9910
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		01.9910
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9910
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9710
chemdatabank.com